Amyris signs Biofene supply deal worth expected $100m

Published: 28-Apr-2016

Renewable products company has agreed to supply a nutraceuticals company

Amyris, a renewable products company, has signed a five year supply agreement with a global nutraceuticals company, which Amyris predicts to generate $100m in revenues from.

The agreement relates to the supply of Biofene, Amyris’ brand of a long-chain, branched hydrocarbon molecule called farnesene. Farnesene is used to form the basis of a wide range of cosmetics products.

John Melo, President & CEO of Amyris, said: "This agreement represents a new highly disruptive partner application for our flexible Biofene ingredient ─ which supports multiple broad-based market applications and further solidifies Amyris' track record of helping solve partners' supply and product margin needs by supplying cost-advantaged renewable ingredients that perform better than current supply sources. We are experiencing significant growth in demand for our Biofene and Biofene-derivative applications from large markets such as tires, industrial lubricants, solvents, and nutraceuticals. This demand growth is accelerating our mission to make renewable products mainstream while making our company sustainable."

You may also like